RESUMO
A 25-year-old woman with a history of B-cell acute lymphoblastic leukemia over ten years ago was referred to our hospital with a chief complaint of leukoblastosis. She was participating in a JPLSG (Japanese Pediatric Leukemia/Lymphoma Study Group) clinical study at that time. We diagnosed ALL relapse by multi-color flow cytometric analysis of bone marrow samples at admission, with reference to previous JPLSG data. Because her leukemic cells were resistant to conventional cytotoxic agents, she proceeded to lymphocyte apheresis for chimeric antigen receptor T-cell (CAR-T, Tisagenlecleucel [Tisa-cel]). She received two cycles of inotuzumab ozogamicin as a bridging therapy to Tisa-cel, resulting in a hematological complete remission (minimal residual disease measured by polymerase chain reaction [PCR-MRD] was positive at 1.0×10-4). She was finally administered Tisa-cel and achieved MRD negativity. She is currently in complete remission with careful MRD monitoring. This strategy of sequential bi-targeted therapy combining antibody conjugates and CAR-T cells provides tumor control in deeper remission and minimal damage to organ function through reduced use of cytotoxic anti-tumor agents. Therefore, we believe that this therapeutic strategy is an effective and rational treatment for adolescent and young adult ALL patients.
Assuntos
Linfoma de Burkitt , Leucemia-Linfoma Linfoblástico de Células Precursoras , Humanos , Adolescente , Feminino , Criança , Adulto Jovem , Adulto , Inotuzumab Ozogamicina/uso terapêutico , Imunoterapia Adotiva , Cromossomo Filadélfia , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapiaRESUMO
BACKGROUND: Information regarding the status of surgical antimicrobial prophylaxis (SAP) in Japanese hospitals is lacking. This study aimed to explore the status of SAP prescriptions for surgeries and adherence to Japanese SAP guidelines. METHODS: From February to July 2020, a 1-day multicentre point prevalent survey was conducted at 27 hospitals in Aichi Prefecture, Japan. Patients prescribed SAP were included in this study. The appropriateness of the SAP was evaluated based on the guidelines for selection of antimicrobials and their duration. Surgery was defined as appropriate when all the items were appropriate. RESULTS: A total of 728 patients (7.1 %; 728/10,199) received antimicrobials for SAP. Among them, 557 patients (76.5 %, 557/728) underwent the surgeries described in the guidelines. The overall appropriateness of all surgeries was 33.9 % (189/557). The appropriate selection of antimicrobial before/during and after surgery and their durations were 67.5 % (376/557), 67.5 % (376/557), and 43.3 % (241/557), respectively. The overall appropriateness ranged from 0 % (0/37, oral and maxillofacial surgery) to 58.7 % (88/150, orthopaedic surgery) and 27.7 % (36/130, community hospitals with 400-599 beds) to 47.2 % (17/36, specific hospitals). Cefazolin was the most prevalent antimicrobial prescribed before/during (55.5 %, 299/539), and after (45.1 %, 249/552) surgery. In total, 101 oral antimicrobials were prescribed postoperatively. CONCLUSIONS: SAP adherence by specific surgical fields and hospitals was shown in this study. Intensive intervention and repeated surveillance are necessary to improve SAP prescriptions in Japanese hospitals.
Assuntos
Antibioticoprofilaxia , Fidelidade a Diretrizes , Hospitais , Infecção da Ferida Cirúrgica , Humanos , Japão , Antibioticoprofilaxia/estatística & dados numéricos , Antibioticoprofilaxia/métodos , Antibioticoprofilaxia/normas , Infecção da Ferida Cirúrgica/prevenção & controle , Fidelidade a Diretrizes/estatística & dados numéricos , Hospitais/estatística & dados numéricos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Antibacterianos/uso terapêutico , Adulto , Guias de Prática Clínica como Assunto , Idoso de 80 Anos ou mais , População do Leste AsiáticoRESUMO
A 16-year-old boy received an unrelated bone marrow transplant while in second remission of acute myeloid leukemia. He suffered from severe oral mucosal complications and had difficulty taking oral drugs such as sulfamethoxazole/trimethoprim (ST). Engraftment was obtained on transplant day 35, and blurred vision and headache appeared around transplant day 60. Funduscopy revealed retinal hemorrhage and macular edema, and an MRI scan of the head revealed a nodular lesion in the left putamen. Toxoplasma gondii was detected by CSF PCR, and cerebral toxoplasmosis was diagnosed. Following therapy with ST and clindamycin, the patient was administered pyrimethamine, sulfadiazine, and leucovorin. Symptoms improved promptly, and CSF PCR was negative 45 days after the start of treatment. Since the prevalence of toxoplasma antibodies increases with age, it is crucial to avoid toxoplasma reactivation by ST after hematopoietic cell transplantation in postpubescent patients.
Assuntos
Transplante de Células-Tronco Hematopoéticas , Leucemia Mieloide Aguda , Toxoplasma , Toxoplasmose Cerebral , Masculino , Humanos , Adolescente , Toxoplasmose Cerebral/diagnóstico , Toxoplasmose Cerebral/tratamento farmacológico , Toxoplasmose Cerebral/etiologia , Transplante de Medula Óssea/efeitos adversos , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Leucemia Mieloide Aguda/tratamento farmacológicoRESUMO
A 34-year-old man with no medical history presented with fever 4 days after receiving the first dose of mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine. He had no prior clinical evidence of severe acute respiratory syndrome coronavirus 2 infection and was negative for serial polymerase chain reaction testing. Ten days after vaccination, he was referred to our hospital because of no response to antibiotics and the emergence of neutropenia, thrombocytopenia, and liver dysfunction. Blood tests also showed elevated serum ferritin and plasma soluble interleukin-2 receptors. Serological and PCR testing excluded active infections of cytomegalovirus, Epstein-Barr virus, and hepatitis viruses. Blood culture yielded no growth. Computed tomography revealed mild hepatosplenomegaly and porta hepatis lymphadenopathy but no focus on infection. Bone marrow aspiration demonstrated hemophagocytosis but no infiltrating lymphoma cells. Immediately, 2-mg/kg intravenous methylprednisolone was commenced based on the presumptive diagnosis of hemophagocytic lymphohistiocytosis (HLH), leading to the rapid and durable improvement of his symptoms and laboratory data. Later, without other causes triggering hemophagocytosis, and with the close link between vaccination and disease onset, the final diagnosis of vaccination-induced secondary HLH was made. HLH after COVID-19 vaccination, though extremely rare, can occur regardless of the vaccine type. Therefore, clinicians should recognize and deal with this occasionally fatal adverse event.
Assuntos
COVID-19 , Infecções por Vírus Epstein-Barr , Humanos , Adulto , Vacinas contra COVID-19/efeitos adversos , COVID-19/prevenção & controle , Vacina de mRNA-1273 contra 2019-nCoV , Herpesvirus Humano 4RESUMO
A 26-year-old woman complained of upper abdominal pain. Computed tomography (CT) showed acute pancreatitis, a left adrenal tumor and solitary right pulmonary metastasis. She underwent left adrenalectomy; the adrenal tumor was diagnosed as adrenocortical carcinoma (ACC). When preparing to resect the pulmonary metastasis, she suffered a second acute pancreatic attack. Magnetic resonance cholangiopancreatography (MRCP) showed that the proximal main pancreatic duct (MPD) was dilated, and the distal MPD was diminished; however, no pancreatic tumor was observed on CT or MRCP. Endoscopic ultrasonography revealed a solitary pancreatic mass, which was diagnosed as pancreatic metastasis from ACC by endoscopic ultrasonography-guided fine-needle aspiration.
Assuntos
Neoplasias do Córtex Suprarrenal/complicações , Carcinoma Adrenocortical/complicações , Biópsia por Agulha Fina/métodos , Endossonografia/métodos , Neoplasias Pancreáticas/diagnóstico , Pancreatite/diagnóstico , Doença Aguda , Adulto , Feminino , Humanos , Ductos Pancreáticos/patologiaRESUMO
A 78-year-oldman was referredto our hospital for right abdominal pain. The patient was diagnosedwith xanthogranulomatous cholecystitis(XGC)at the gallbladder fundus and adenomyomatosis(ADM)at the gallbladder neck. Because malignancy was undeniable, laparotomy was performed. Frozen section examination of the excised whole-layer gallbladder revealed cancer cells at the gallbladder neck and cystic duct. Therefore, additional gallbladder bed resection, extrahepatic bile duct resection, and lymphadenectomy were performed. The final diagnosis, based on the histopathological examination of all resected specimens, was gallbladder adenocarcinoma(T3aN0M0, Stage â ¢A). ADM was not observedat the same sites as the adenocarcinoma. The fundus lesion was diagnosed as XGC. Here, we report our rare case of XGC coexisting with gallbladder cancer.
Assuntos
Colecistite , Neoplasias da Vesícula Biliar , Xantomatose , Idoso , Colecistite/diagnóstico , Colecistite/cirurgia , Neoplasias da Vesícula Biliar/diagnóstico , Neoplasias da Vesícula Biliar/cirurgia , Granuloma , Humanos , Masculino , Xantomatose/diagnóstico , Xantomatose/cirurgiaRESUMO
Pharmacokinetic-pharmacodynamic systems are often expressed with nonlinear ordinary differential equations (ODEs). While there are numerous methods to solve such ODEs these methods generally rely on time-stepping solutions (e.g. Runge-Kutta) which need to be matched to the characteristics of the problem at hand. The primary aim of this study was to explore the performance of an inductive approximation which iteratively converts nonlinear ODEs to linear time-varying systems which can then be solved algebraically or numerically. The inductive approximation is applied to three examples, a simple nonlinear pharmacokinetic model with Michaelis-Menten elimination (E1), an integrated glucose-insulin model and an HIV viral load model with recursive feedback systems (E2 and E3, respectively). The secondary aim of this study was to explore the potential advantages of analytically solving linearized ODEs with two examples, again E3 with stiff differential equations and a turnover model of luteinizing hormone with a surge function (E4). The inductive linearization coupled with a matrix exponential solution provided accurate predictions for all examples with comparable solution time to the matched time-stepping solutions for nonlinear ODEs. The time-stepping solutions however did not perform well for E4, particularly when the surge was approximated by a square wave. In circumstances when either a linear ODE is particularly desirable or the uncertainty in matching the integrator to the ODE system is of potential risk, then the inductive approximation method coupled with an analytical integration method would be an appropriate alternative.
Assuntos
Modelos Biológicos , Farmacologia/métodos , Algoritmos , Linfócitos T CD4-Positivos/virologia , Feminino , Glucose/metabolismo , Hormônio Liberador de Gonadotropina/análogos & derivados , Hormônio Liberador de Gonadotropina/farmacologia , HIV/fisiologia , Humanos , Insulina/farmacologia , Modelos Lineares , Hormônio Luteinizante/metabolismo , Dinâmica não Linear , Ovulação/efeitos dos fármacos , Ovulação/metabolismo , Carga ViralRESUMO
Lignosulfonic acid is a waste lignin produced from the sulfite pulping of softwood. We investigated the effect of lignosulfonic acid on α-glucosidase and found that lignosulfonic acid produced a reversible and non-competitive inhibition of the enzyme activity. Moreover, in human colorectal adenocarcinoma cells, lignosulfonic acid inhibited 2-deoxyglucose uptake, while in vivo studies demonstrated a significant reduction in the blood glycemic response to sucrose or glucose ingestion in rats treated with lignosulfonic acid. Feces of rats fed a diet supplemented with 5% lignosulfonic acid had higher sugar content compared to those of rats fed a control diet. These results suggest that lignosulfonic acid suppresses the rise in blood glucose levels through inhibition of α-glucosidase activity and intestinal glucose absorption.
Assuntos
Glucose/metabolismo , Inibidores de Glicosídeo Hidrolases/farmacologia , Absorção Intestinal/efeitos dos fármacos , Lignina/farmacologia , Extratos Vegetais/farmacologia , Ácidos Sulfônicos/farmacologia , alfa-Glucosidases/metabolismo , Células 3T3-L1 , Animais , Glicemia/metabolismo , Células CACO-2 , Metabolismo dos Carboidratos/efeitos dos fármacos , Linhagem Celular Tumoral , Colo/efeitos dos fármacos , Colo/metabolismo , Desoxiglucose/metabolismo , Suplementos Nutricionais , Fezes/química , Humanos , Resíduos Industriais , Mucosa Intestinal/metabolismo , Intestinos/efeitos dos fármacos , Masculino , Camundongos , Ratos Wistar , Madeira/químicaRESUMO
ONO-5334, a selective inhibitor of cathepsin K, is a potential new treatment for osteoporosis. The objectives of this study were to (1) develop population pharmacokinetic-pharmacodynamic (PK-PD) models for ONO-5334 using dose-ascending data from healthy postmenopausal females, (2) examine comparability of PK and/or PD profile between Caucasian and Japanese, and (3) compare PK-PD profile between immediate release tablet (IRT) and sustained release tablet (SRT). The population PK-PD models were developed for each formulation for post-dose levels of bone resorption markers (serum CTX and NTX). The data were provided from 4 phase 1 studies with total of 201 Caucasian and 94 Japanese subjects. Plasma concentrations of ONO-5334 and bone resorption markers were thoroughly evaluated in those studies. An indirect response model described relationships between bone resorption markers and plasma concentrations of ONO-5334. There was no significant difference in PK and pharmacodynamic potency (IC50 ) between Caucasian and Japanese. Based on the developed model, serum CTX and NTX after administration of ONO-5334 IRT or SRT were simulated, and the results showed that ONO-5334 SRT would provide comparable PD effect on bone resorption markers with lower dose relative to IRT.
Assuntos
Catepsina K/antagonistas & inibidores , Inibidores de Cisteína Proteinase/farmacocinética , Pós-Menopausa/metabolismo , Tiazolidinas/farmacocinética , Idoso , Algoritmos , Área Sob a Curva , Povo Asiático , Peso Corporal/fisiologia , Química Farmacêutica , Cromatografia Líquida de Alta Pressão , Inibidores de Cisteína Proteinase/administração & dosagem , Relação Dose-Resposta a Droga , Europa (Continente) , Feminino , Humanos , Japão , Pessoa de Meia-Idade , Modelos Estatísticos , Espectrometria de Massas em Tandem , Tiazolidinas/administração & dosagem , População BrancaRESUMO
Pranlukast is a cysteinyl leukotriene receptor antagonist that has been used to treat bronchial asthma and allergic rhinitis. In vitro data suggest that pranlukast is a substrate of CYP3A4. Thus, the effect of clarithromycin, a potent CYP3A4 inhibitor, on the pharmacokinetics of pranlukast was examined in an open-label, randomized, two-way crossover study in 16 healthy male volunteers. In treatment A, volunteers received a single, 225 mg dose of pranlukast. In treatment B, 200 mg of clarithromycin was administered twice daily for 7 days and a single, 225 mg dose of pranlukast was coadministered on day 7. Blood samples were collected up to 24 hours after treatment, and pranlukast concentrations in the plasma were measured. The geometric mean ratios [GMR] (90% confidence intervals [CIs]) for pranlukast AUC(0-infinity) and C(max) (with/without clarithromycin) were 1.06 (0.91, 1.24) and 1.17 (0.95, 1.45), respectively. In conclusion, clarithromycin and pranlukast could be coadministered without dose adjustment because clarithromycin minimally affected the pharmacokinetics of pranlukast.